Cullinan Therapeutics, Inc. financial data

Symbol
CGEM on Nasdaq
Location
Cambridge, MA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 06 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1137% % -49%
Debt-to-equity 6% % 19%
Return On Equity -42% % -57%
Return On Assets -39% % -55%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 59,076,259 shares 1.5%
Common Stock, Shares, Outstanding 59,076,259 shares 1.6%
Entity Public Float $1,000,000,000 USD 167%
Common Stock, Value, Issued $6,000 USD 0%
Weighted Average Number of Shares Outstanding, Basic 58,337,000 shares 37%
Weighted Average Number of Shares Outstanding, Diluted 58,337,000 shares 37%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $184,949,000 USD 35%
General and Administrative Expense $56,488,000 USD 13%
Operating Income (Loss) $241,437,000 USD -29%
Net Income (Loss) Attributable to Parent $216,813,000 USD -51%
Earnings Per Share, Basic -2 USD/shares 25%
Earnings Per Share, Diluted -2 USD/shares 24%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $103,335,000 USD 1.2%
Cash, Cash Equivalents, and Short-term Investments $332,600,000 USD -42%
Assets, Current $342,235,000 USD -42%
Property, Plant and Equipment, Net $489,000 USD -36%
Operating Lease, Right-of-Use Asset $1,046,000 USD -48%
Other Assets, Noncurrent $361,000 USD -22%
Assets $484,126,000 USD -26%
Accounts Payable, Current $1,722,000 USD -19%
Accrued Liabilities, Current $29,847,000 USD 43%
Liabilities, Current $32,757,000 USD 35%
Operating Lease, Liability, Noncurrent $0 USD -100%
Liabilities $32,757,000 USD 29%
Accumulated Other Comprehensive Income (Loss), Net of Tax $973,000 USD 0.31%
Retained Earnings (Accumulated Deficit) $537,406,000 USD -68%
Stockholders' Equity Attributable to Parent $451,369,000 USD -28%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $451,369,000 USD -28%
Liabilities and Equity $484,126,000 USD -26%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $43,155,000 USD -13%
Net Cash Provided by (Used in) Financing Activities $0 USD -100%
Net Cash Provided by (Used in) Investing Activities $36,805,000 USD 184%
Common Stock, Shares Authorized 150,000,000 shares 0%
Common Stock, Shares, Issued 59,076,259 shares 1.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Deferred Tax Assets, Valuation Allowance $130,939,000 USD 50%
Deferred Tax Assets, Gross $131,543,000 USD 49%
Operating Lease, Liability $1,188,000 USD -51%
Payments to Acquire Property, Plant, and Equipment $0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $216,810,000 USD -53%
Lessee, Operating Lease, Liability, to be Paid $1,238,000 USD -54%
Property, Plant and Equipment, Gross $1,341,000 USD 0%
Operating Lease, Liability, Current $1,188,000 USD -5.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two $872,000 USD -40%
Lessee, Operating Lease, Liability, to be Paid, Year One $872,000 USD -40%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $50,000 USD -79%
Deferred Tax Assets, Operating Loss Carryforwards $32,148,000 USD 123%
Preferred Stock, Shares Issued 647,500 shares 0%
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Preferred Stock, Shares Outstanding 647,500 shares 0%
Depreciation, Depletion and Amortization $76,000 USD 0%
Deferred Tax Assets, Net of Valuation Allowance $604,000 USD -34%
Share-based Payment Arrangement, Expense $38,362,000 USD 7.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%